2026-04-23T01:34:04Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/577282025-09-03T10:12:57Zcom_10324_1132com_10324_931com_10324_894col_10324_1205

Fernández Lázaro, Diego Fernández Lázaro, César Ignacio Caballero García, Alberto Córdova Martínez, Alfredo 2018 Producción Científica Thalidomide changed the treatment of patients with multiple myeloma, however, its effectiveness has been compromised due to its side effects. New strategies are needed to specifically target the challenges of multiple myeloma through innovative, more effective, and less toxic therapy. The new immunomodulatory (IMiDs) compounds are structural and functional analogs of thalidomide, which were designed to improve the immunomodulatory and anticancer properties and tolerability profiles. We review the development of second generation IMiDs, lenalidomide and pomalidomide, their immunomodulatory and tumoricidal effects, their mechanisms of action, as well as the influence of dexamethasone on their effect and pharmacological resistance. In conclusion, lenalidomide and pomalidomide demonstrate a powerful activity and they are highly effective and well-tolerated treatment options for patients with myeloma, used alone or in combination with dexamethasone. application/pdf https://uvadoc.uva.es/handle/10324/57728 spa Sociedad Médica de Santiago Multiple myeloma - Treatment Multiple myeloma - Diagnosis Immunology 3207.13 Oncología 3207.08 Hematología Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple info:eu-repo/semantics/article Immunomodulator drugs for the treatment of multiple myeloma TEXT UVaDOC. Repositorio Documental de la Universidad de Valladolid Hispana